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Abstract 
Review on GLS2, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Identity 
Other names: GA; PAG (phosphate-activated 
glutaminase); GAB; LGA (liver-type glutaminase); 
hLGA 
HGNC (Hugo): GLS2 (Glutaminase 2 (liver, 
mitochondrial)) 
Location: 12q13.3 
DNA/RNA 
Description 
GLS2 gene is composed of 18 exons, with a length 
of approximately 18 kbases (Pérez-Gómez et al., 
2003). Position 56864728 to 56882198, minus strand 
(NCBI, 27165). 
Transcription 
Two sense GLS2 transcripts have been identified: a 
long canonical one containing all 18 exons (GAB, 
2.4 kb)(Gómez-Fabre et al., 2000) and a short variant 
(LGA, 1.9 kb) lacking the first exon (Martín-Rufián 
et al., 2012).  
Genomic structure of GLS2 gene and mRNA transcripts. Introns are depicted as solid orange lines and exons as numbered blue 
boxes. Dashed red or dotted green lines indicate the exons involved in the generation of GAB and LGA transcripts, respectively. 
Modified from Márquez et al., BioMol. Concepts, 1, 3-15 (2010). 
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Schematic diagram of GLS2 isoforms showing the localization of predicted domains and motifs by sequence analysis. 
 
LGA transcript appears by alternative transcription 
initiation and has an alternative promoter, with its 
transcription start site located at 3-end of first intron 
of GLS2 gene. Other non-coding transcripts, 
containing premature stop codons, have been 
isolated. GLS2 transcription can be regulated by p53 
and p63 tumour suppressors (Hu et al., 2010; Suzuki 
et al., 2010; Giacobbe et al., 2013). 
Pseudogene 
At least one reported pseudogene for GLS2 
(GenBank: AF110329.1). 
Protein 
Note 
To date, any GLS2 isoform has been isolated from 
human tissues or cells, so all information about 
protein structure or posttranslational modifications 
derive from bioinformatic analysis. 
Description 
GAB transcript (1809 bps ORF) codes a 602-
residues protein, with a predicted molecular mass of 
66309 Da. LGA transcript (1698 bps ORF) codes a 
565-residues protein, with a predicted molecular 
mass of 62496 Da. The precursor of LGA isoform 
lacks the first 61 residues at the N-terminal region of 
GAB precursor (coded by exon 1), but it displays an 
additional extension of 24 residues at the N-terminus 
coded by an alternative first exon. 
GLS2 contains a catalytic domain (glutaminase 
domain) of approx. 300 residues, 2 ankyrin repeats 
at the C-terminal region and a consensus sequence of 
4 residues at the C-terminal end required for specific 
interaction with PDZ proteins, as alpha-syntrophin 
(SNT) and Glutaminase-Interacting Protein (GIP) 
(Olalla et al., 2001). The N-terminal end (first 14 
residues) of GAB precursor contains a putative 
mitochondrial import presequence (Gómez-Fabre et 
al., 2000). It is worth mentioning the presence of a 
consensus LXXLL motif of interaction with nuclear 
receptors at N-terminal region of GLS2 (Olalla et al., 
2002). 
Expression 
Brain, liver, pancreas, human cancer cells (Gómez-
Fabre et al., 2000 ; Aledo et al., 2000 ; Pérez-Gómez 
et al., 2005), cells of immune system (Castell et al., 
2004). 
Localisation 
Mitochondrial. A nuclear localization has also been 
reported for neurons (Olalla el al., 2002). 
Function 
GLS2 (E.C. 3.5.1.2.) catalyzes the hydrolytic 
deamidation of L-glutamine to form L-glutamate and 
ammonium, the first step of glutaminolysis. As 
shown in recent works, GLS2 overexpression in 
glioblastoma cell lines caused a reversion of their 
transformed phenotype (Szeliga et al., 2009). This is 
in agreement with the loss of GLS2 expression in 
hepatocellular carcinomas (Suzuki et al., 2010) and 
brain tumours (Szeliga et al., 2005). So, GLS2 may 
play a role as tumour suppressor, in opposition to 
that of GLS, regulated by oncogenes and associated 
to tumorigenesis. However, this behavior of GLS2 is 
not universal, as there are some types of cancer -like 
cervical cancer- where upregulation of GLS2 occurs, 
conferring therapeutic resistance (Xiang et al., 
2013). 
Implicated in 
Glioblastoma (WHO grade IV). 
GLS2 expression is downregulated in highly 
malignant glioblastoma (Szeliga et al., 2005 and 
2009). One of the mechanisms involved in this gene 
silencing was recently demonstrated to be promoter 
methylation and not related to the p53  status 
(Szeliga et al., 2015). Human glioblastoma T98G 
cells stably transfected with the full GLS2 cDNA 
coding sequence showed a reversion of their  
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malignant phenotype, including a marked inhibition 
in growth and proliferation (Szeliga et al., 2009), 
down-regulation of the expression of DNA-repair 
gene MGMT   and sensitization to alkylating agents 
(Szeliga et al., 2012). ROS generation by treatment 
with oxidizing agents synergized with GLS2 
overexpression in T98G glioma cells to suppress 
their malignant properties, including the reduction of 
cellular mobility (Martín-Rufián et al., 2015). 
Hepatocellular Carcinoma 
Two research groups identified GLS2 as a target for 
p53 tumor suppressor gene (Hu et al., 2010; Suzuki 
et al., 2010). GLS2 is frequently downregulated or 
repressed in some types of cancer, like human 
hepatocellular carcinoma (Yuneva et al., 2012). It is 
remarkable that GLS2 transcripts were almost absent 
or significantly decreased in hepatocellular 
carcinomas compared to normal liver tissue, where 
GLS2 is abundantly expressed (Suzuki et al. 2010). 
These findings support the hypothesis that repression 
of GLS2 is a frequent trait associated with 
tumorigenesis. Hence, the authors suggested a 
potential tumor suppressor role for GLS2 (Suzuki et 
al. 2010). Of interest, it has been demonstrated that 
GLS2 can be transcriptionally regulated by TP63, a 
transcription factor belonging to the p53 family 
(Giacobbe et al. 2013). 
Cervical Carcinoma 
Expression of GLS2 was significantly enhanced in 
cervical carcinoma and related to therapeutic 
resistance (Xiang et al., 2013). 
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